None listed
Conditions
Interventions
Group 1:PegIFNa-2b± Propofol tenofovir fumarate tablets (TAF) for continuous treatment
Group 2:PegIFNa-2b± Propofol tenofovir fumarate tablets (TAF) intermittent treatment
Control group:None
Sponsors
Beijing You'an Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-60 years (including 18 and 60 years old); 2. HBsAg positive >6 months, continuous HBsAg < 1000IU/ml, HBeAg negative, anti-HBC positive; 3. HBV DNA persistence < 2000IU/ml; 4. ALT remains normal (<40U/L) (Note: ''Continuous'' is defined as at least two tests within a year, with an interval of 3-6 months).
Exclusion criteria
Exclusion criteria: 1. Patients with HAV, HCV, HDV, HEV infection and autoimmune liver disease; 2. Pregnant and lactating patients and patients who plan to give birth recently; 3. History of serious heart disease, including unstable or uncontrolled heart disease within 6 months; 4. History of mental illness; 5. Uncontrolled seizures; 6. Alcohol or drug abusers in remission; 7. Uncontrolled diabetes, hypertension, thyroid disease, retinopathy, autoimmune disease, etc.; 8. Total bilirubin >34umol/L; 9. Patients with previous or current liver cirrhosis or liver cancer confirmed by liver ultrasound or liver stiffness measurement; 10. Neutrophil counts < 2x10^9 /L and/or platelet counts < 100x10^9 /L.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hepatitis B surface antigen clearance; | — |
Secondary
| Measure | Time frame |
|---|---|
| hepatitis B virus DNA;liver stiffness;cirrhosis;hepatocellular carcinoma;hepatitis B virus RNA;hepatic cccDNA; | — |
Countries
China
Contacts
Public ContactChen Xinyue
Outcome results
None listed